Angiosuppression and chemotherapy: strategies aimed at their integration in cancer patients.
A number of antiangiogenic agents have been developed as pharmaceuticals and are currently being tested in clinical studies. Potential strategies to enhance the activity of angiogenesis inhibitors could be to combine them, or better still, to administer them either sequentially or concurrently with cytotoxic drugs. Chemotherapy would be a more appropriate initial choice for patients with advanced disease since cytostatic agents can induce a fast regression of the tumor and cancer-related symptoms. Antiangiogenic treatment could be used after chemotherapy in patients who achieve disease remission to prolong the time to progression, the symptom-free interval and the overall survival. Antiangiogenic treatment is likely to attain an important role in the adjuvant setting. In fact, it could be used for prolonged periods after radical surgery to maintain dormancy of residual tumor cells. In spite of these promising preclinical data, several points need to be clarified before the initiation of clinical trials. In fact, certain misconceptions may interfere with their optimum design and result analysis.
Cascinu
S
S
Department of Medical Oncology, University of Messina, Italy.
Valenti
A
A
Amadio
P
P
Mare
M
M
Munaò
S
S
Crucitta
E
E
Raffaele
M
M
Picone
G
G
Mesiti
M
M
Gasparini
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D016228:Endothelial Growth Factors / Q000096:biosynthesis; D006801:Humans; D008222:Lymphokines / Q000096:biosynthesis; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors